Vaccine Blood Clots
On Tuesday, the United States Food and Drug Administration and the United States Center for Disease Control and Prevention put out a statement recommending the U.S. halt the use of Johnson & Johnson’s one shot COVID-19 vaccine. More than 6.8 million doses of Johnson & Johnson’s vaccine have been administered in the United States.
After six patients in the U.S. received Johnson & Johnson’s vaccine, they reported developing a rare and dangerous type of blood clot. In one case, the patient is currently in critical condition, and one case was fatal. All six cases occurred in women aged 18 to 48, and signs of the blood clot appeared 6 to 13 days after vaccination.
In a statement issued by Johnson and Johnson on Tuesday, the company announced they have agreed to “proactively delay the rollout” of its one-shot vaccine in Europe. The company also said while the detrimental side effects are extremely rare, if you’ve received their shot and have had an extreme headache, chest pain, leg pain, or shortness of breath within three weeks of vaccination, call your healthcare provider.
Administering the vaccine was paused because this kind of blood clot is not on the list of the possible nasty side effects included in Johnson & Johnson’s emergency use authorization. Both the CDC and the FDA are investigating further into the matter, and until they reach a conclusion, they are recommending halting the use of Johnson and Johnson’s vaccine — it is better to be safe than sorry.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.
